Daily Ards Research Analysis
Three impactful ARDS studies emerged: a multicenter proteomics cohort defining and validating three inflammatory phenotypes with differential treatment responses; a mechanistic study identifying a miR-24/BOK axis that mitigates ventilator-induced lung injury; and a longitudinal multi-omics murine influenza model revealing time-dependent matrisome remodeling and fibroblast heterogeneity linked to post-ARDS fibrosis.
Summary
Three impactful ARDS studies emerged: a multicenter proteomics cohort defining and validating three inflammatory phenotypes with differential treatment responses; a mechanistic study identifying a miR-24/BOK axis that mitigates ventilator-induced lung injury; and a longitudinal multi-omics murine influenza model revealing time-dependent matrisome remodeling and fibroblast heterogeneity linked to post-ARDS fibrosis.
Research Themes
- Proteomic phenotyping and precision medicine in ARDS
- MicroRNA-mediated mechanisms of ventilator-induced lung injury
- Fibroblast and extracellular matrix remodeling after viral lung injury
Selected Articles
1. Large-scale proteomic profiling identifies distinct inflammatory phenotypes in Acute Respiratory Distress Syndrome (ARDS): A multi-center, prospective cohort study.
In a multicenter prospective cohort of 1048 ARDS patients, latent class analysis of early serum proteomics defined three inflammatory phenotypes with distinct clinical, radiographic, and molecular features. The high-risk C1 phenotype had the worst 90-day outcomes and different responses to steroids and ventilation, supporting biomarker-guided precision therapies.
Impact: This study integrates proteomics, radiomics, and causal-inference analyses to validate actionable ARDS phenotypes with heterogeneous treatment effects, advancing precision medicine.
Clinical Implications: Phenotype assignment at diagnosis could stratify risk and inform steroid use and ventilation strategies. Implementing a parsimonious classifier may enable bedside biomarker-guided care.
Key Findings
- Three proteomic inflammatory phenotypes (C1–C3) were identified and externally validated among 1048 ARDS patients.
- C1 had greater poorly/non-inflated lung on CT, highest 90-day mortality and shock, and fewest ventilator-free days.
- Phenotypes demonstrated heterogeneous treatment effects to glucocorticoids and ventilation; an XGBoost classifier enabled phenotype prediction.
Methodological Strengths
- Multicenter prospective design with early serum sampling and external validation
- Integrated omics (proteomics) with radiomics and IPTW-adjusted HTE analyses
Limitations
- Non-randomized treatment exposure may confound heterogeneous treatment effect estimates
- Serum proteomics may not fully reflect lung compartment biology
Future Directions: Prospective stratified or adaptive trials should test phenotype-guided therapies and validate parsimonious biomarker panels for bedside use.
BACKGROUND: Host responses during ARDS are highly heterogeneous, contributing to inconsistent therapeutic outcomes. Proteome-based phenotyping may identify biologically and clinically distinct phenotypes to guide precision therapy. METHODS: In this multicenter cohort study, we used latent class analysis (LCA) of targeted serum proteomics to identify ARDS phenotypes. Serum samples were collected within 72 h of diagnosis to capture early-phase profiles. Validation was conducted in external cohorts. Pathway enrichment assessed molecular heterogeneity. Lung CT scans were analyzed using machine learning-based radiomics to explore phenotypic distinctions. Heterogeneous treatment effects (HTEs) for glucocorticoids and ventilation strategies were evaluated using inverse probability of treatment weighting (IPTW) adjusted Cox regression. A multinomial XGBoost model was developed to classify phenotypes. RESULTS: Among 1048 patients, three inflammatory phenotypes (C1, C2, C3) were identified and validated in two independent cohorts. The phenotype C1 with a larger proportion of poorly/non-inflated lung compartments had the highest 90-day mortality, shock incidence, and fewest ventilator-free days, followed by C3, while C2 patients had the best outcomes ( CONCLUSIONS: We identified and validated three proteome-based ARDS phenotypes with distinct clinical, radiographic, and molecular profiles. Their differential treatment responses highlight the potential of biomarker-driven strategies for ARDS precision medicine.
2. MiR-24 Attenuates Oxidative Stress and Mitochondrial Apoptosis in Ventilator-Induced Lung Injury by Targeting Bcl-2-related Ovarian Killer.
Across ARDS patient plasma, rat VILI, and cyclic-stretch cell models, miR-24 was downregulated and inversely related to BOK. miR-24 overexpression suppressed inflammation, oxidative stress, and mitochondrial apoptosis, whereas BOK overexpression abrogated these effects, defining a therapeutic miR-24/BOK axis with diagnostic potential (AUC 0.834).
Impact: This study establishes a mechanistic microRNA-to-effector pathway in VILI with convergent in vivo and in vitro validation and identifies a dual biomarker/therapeutic candidate.
Clinical Implications: While preclinical, targeting the miR-24/BOK axis could mitigate VILI and inform biomarker development for ARDS patients on mechanical ventilation.
Key Findings
- miR-24 is downregulated in ARDS patient plasma, rat VILI lungs, and stretch-exposed alveolar epithelial cells and correlates with oxygenation.
- miR-24 directly targets BOK; overexpression of miR-24 reduces inflammation, oxidative stress, and mitochondrial apoptosis in vivo and in vitro.
- BOK silencing mimics, and BOK overexpression reverses, the protective effects of miR-24; ROC analysis shows diagnostic utility (AUC 0.834).
Methodological Strengths
- Convergent validation across patient biospecimens, animal VILI model, and cell stretch assays
- Mechanistic rigor with luciferase reporter, RNA pull-down, and rescue experiments (BOK overexpression/silencing)
Limitations
- Preclinical design limits direct clinical generalizability
- Sample sizes for patient plasma and some experiments are not specified in the abstract
Future Directions: Quantify effect sizes in large animal models, assess safety/efficacy of miR-24 delivery, and validate circulating miR-24/BOK as predictive biomarkers in clinical cohorts.
Mechanical ventilation (MV), though life-saving in acute respiratory distress syndrome (ARDS), can cause ventilator-induced lung injury (VILI). MicroRNA-24 (miR-24) has been implicated in regulating inflammation and apoptosis, but its role in VILI remains unexplored. Therefore, our study aimed to explore the role of mechanism of miR-24 in VILI. MiR-24 expression was analyzed in MV-induced ARDS rat models (GSE57223), plasma from ARDS patients, and cyclic stretch (CS)-treated alveolar epithelial cells. Functional studies included intratracheal delivery of miR-24-agomir in rats with VILI and transfection of miR-24 mimic in CS-exposed cells. Inflammatory cytokines, oxidative stress markers, apoptosis, and mitochondrial dysfunction were assessed using ELISA, RT-qPCR, TUNEL, JC-1 staining, and ATP assays. BOK was identified as a target of miR-24 via bioinformatics, luciferase reporter, and RNA pull-down assays. Rescue experiments using BOK overexpression vectors (pcDNA3.1/BOK) were conducted in both models to confirm functional interaction. MiR-24 was significantly downregulated in ARDS patients and VILI models and positively correlated with oxygenation index. Overexpression of miR-24 attenuated MV- and CS-induced inflammation, oxidative damage, and mitochondrial apoptosis dysfunction. BOK was confirmed as a direct target of miR-24; its expression was upregulated in ARDS and VILI and inversely correlated with miR-24 levels. Silencing of BOK attenuated MV-induced inflammation, oxidative damage, and apoptosis in rats. Importantly, BOK overexpression reversed the protective effects of miR-24 both in vivo and in vitro, confirming its role as a key downstream effector. Receiver operating characteristic (ROC) analysis showed that miR-24 had good diagnostic potential (AUC = 0.834). Overall, MiR-24 protects against MV-induced lung injury by targeting BOK and modulating key injury pathways. The miR-24/BOK axis offers a promising therapeutic avenue for ARDS-associated VILI.
3. Integrated Longitudinal Transcriptomic and Proteomic Analysis of the Murine Lung Response to Influenza A Virus.
Using longitudinal single-cell transcriptomics and TMT-based proteomics in an influenza A murine model, the study reveals dynamic remodeling of the lung matrisome peaking around day 10 post-infection and transcriptional heterogeneity among proximal/adventitial fibroblasts. These findings provide mechanistic insights into post-ARDS fibrotic responses following viral injury.
Impact: Integrative multi-omics dissects time-resolved ECM remodeling and fibroblast heterogeneity, addressing a key knowledge gap in ARDS-associated fibrotic progression after viral pneumonia.
Clinical Implications: Identifying windows of peak ECM remodeling (around day 10) and fibroblast subsets may inform timing and targets for antifibrotic interventions after severe viral ARDS.
Key Findings
- Longitudinal TMT-LC/LC-MS/MS showed profound changes in the lung matrisome, most evident at day 10 post-influenza infection.
- Single-cell gene expression profiling revealed transcriptional heterogeneity among proximal/adventitial fibroblasts.
- Integrated multi-omics highlights dynamic ECM remodeling as a mechanistic substrate for post-ARDS fibrotic responses.
Methodological Strengths
- Integrated longitudinal single-cell transcriptomics with quantitative, multiplexed proteomics (TMT-LC/LC-MS/MS)
- Time-resolved sampling capturing the peak of ECM remodeling
Limitations
- Findings derived from a murine model may not fully translate to human ARDS
- Abstract truncation limits detailed characterization of fibroblast subpopulations in this summary
Future Directions: Map fibroblast lineage trajectories and validate ECM targets in human post-viral ARDS tissues; test timing of antifibrotic interventions in translational models.
Lung injury caused by influenza is a leading cause of respiratory infection-related morbidity and mortality worldwide. In its severe form, influenza can cause acute respiratory distress syndrome (ARDS), which manifests as severe hypoxemic respiratory failure. Survivors of the acute stage of ARDS may develop lung fibrosis. The mechanisms underlying fibrotic responses in this context are unknown. In this study, we investigate fibroblast responses to influenza challenge using single cell gene expression (scGEX) and two-dimensional liquid chromatography coupled with tandem/mass spectrometry (TMT-LC/LC-MS/MS) on lung tissue collected longitudinally in a murine model of influenza A virus (IAV) infection. By TMT-LC/LC-MS/MS, we identified profound changes in the composition of the lung matrisome, which were most evident 10 days after infection. In this context, we identified transcriptional heterogeneity amongst proximal/adventitial fibroblasts expressing